Gilead and Merck Announce Phase 2 Data Showing a Treatment …
1 day ago · Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation in multiple ongoing early and late-stage clinical studies in ...
Gilead and Merck Announce Phase 2 Data Showing a ... - Business …
1 day ago · Studies with islatravir are designed to offer different dosing options as potential daily and once-weekly treatments. For an overview of Merck’s HIV treatment and prevention clinical development ...
Gilead, Merck announce from Phase 2 islatravir/lenacapavir …
17 hours ago · Oct. 20, 2024, 05:00 AM. Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational ...
Combination Investigational HIV Therapy Shows Viral Suppression …
1 day ago · 1.Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48. Gilead press release. October 19, 2024. Accessed October 20, 2024. 2.Colson A, et al. 577 - Week 48 Results of a Phase 2 Study Evaluating ...
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of …
Sep 20, 2022 · The Phase 2 clinical trial (NCT05052996) evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead’s lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir.
Merck Announces Clinical Holds on Studies Evaluating Islatravir …
Dec 13, 2021 · Participants who are currently receiving islatravir as part of the studies for PrEP, including oral and implant formulations, as well as injectable islatravir for treatment and prophylaxis, will no longer receive the study drug; CD4+ T-cell and total lymphocyte counts will be monitored for recovery (full clinical hold).
Gilead And Merck Report Phase 2 Results For Islatravir And …
1 day ago · (RTTNews) - Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational ...
Islatravir plus lenacapavir could be the first once-weekly
Mar 6, 2024 · Islatravir (also known as EFdAor MK-8591) is a first-in-class nucleoside reverse transcriptase translocation inhibitor from Merck. It has a long half-life in the body, making it a candidate for long-acting HIV treatment and prevention.
Promising early results for a once-weekly HIV treatment pill
1 day ago · Newly announced results from a phase 2 clinical trial show that a drug combination—islatravir and lenacapavir—holds promise as the first-ever weekly oral pill for HIV treatment, comparable to a single-tablet regimen taken every day.. At 48 weeks, the drug combo had a 94.2% success rate in keeping adult participants “undetectable,” with an HIV viral load less than 50 copies/mL of blood.
MSD Opens Enrollment in New Phase 3 Clinical Trials with ...
RAHWAY, N.J., Feb. 22, 2023 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK) announced today that the company has opened enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.